197 related articles for article (PubMed ID: 29762783)
1. Repurposing the anthelminthic salicylanilide oxyclozanide against susceptible and clinical resistant Candida albicans strains.
Pic E; Burgain A; Sellam A
Med Mycol; 2019 Apr; 57(3):387-390. PubMed ID: 29762783
[TBL] [Abstract][Full Text] [Related]
2. Synergistic combinations of anthelmintic salicylanilides oxyclozanide, rafoxanide, and closantel with colistin eradicates multidrug-resistant colistin-resistant Gram-negative bacilli.
Domalaon R; Okunnu O; Zhanel GG; Schweizer F
J Antibiot (Tokyo); 2019 Aug; 72(8):605-616. PubMed ID: 31028351
[TBL] [Abstract][Full Text] [Related]
3. Repurposing salicylanilide anthelmintic drugs to combat drug resistant Staphylococcus aureus.
Rajamuthiah R; Fuchs BB; Conery AL; Kim W; Jayamani E; Kwon B; Ausubel FM; Mylonakis E
PLoS One; 2015; 10(4):e0124595. PubMed ID: 25897961
[TBL] [Abstract][Full Text] [Related]
4. In vitro susceptibility of Candida albicans clinical isolates to eight antifungal agents in Ouagadougou (Burkina Faso).
Zida A; Yacouba A; Bamba S; Sangare I; Sawadogo M; Guiguemde T; Kone S; Traore LK; Ouedraogo-Traore R; Guiguemde RT
J Mycol Med; 2017 Dec; 27(4):469-475. PubMed ID: 28754462
[TBL] [Abstract][Full Text] [Related]
5. Repurposing auranofin as an antifungal: In vitro activity against a variety of medically important fungi.
Wiederhold NP; Patterson TF; Srinivasan A; Chaturvedi AK; Fothergill AW; Wormley FL; Ramasubramanian AK; Lopez-Ribot JL
Virulence; 2017 Feb; 8(2):138-142. PubMed ID: 27268469
[TBL] [Abstract][Full Text] [Related]
6. The in vitro antibacterial activity of the anthelmintic drug oxyclozanide against common small animal bacterial pathogens.
Levinson MR; Blondeau JM; Rosenkrantz WS; Plowgian CB
Vet Dermatol; 2019 Aug; 30(4):314-e87. PubMed ID: 31062461
[TBL] [Abstract][Full Text] [Related]
7. Use of Haploid Model of
Truong T; Suriyanarayanan T; Zeng G; Le TD; Liu L; Li J; Tong C; Wang Y; Seneviratne CJ
Front Cell Infect Microbiol; 2018; 8():164. PubMed ID: 29938200
[TBL] [Abstract][Full Text] [Related]
8. Susceptibility and trailing growth of Candida albicans to fluconazole: results of a Korean multicentre study.
Lee MK; Kim HR; Kang JO; Kim MN; Kim EC; Kim JS; Kim JJ; Park YJ; Song W; Shin JH; Lee KM; Lee NY; Lee M; Lee WG; Lee CK; Lee HJ; Chang CL; Choi TY
Mycoses; 2007 Mar; 50(2):148-9. PubMed ID: 17305780
[TBL] [Abstract][Full Text] [Related]
9. Holotoxin A
Liao M; Xia X; Meng Q; Zhu C; Liao B; Wang J; Gou L; Zhou X; Yuan W; Cheng L; Ren B
Br J Pharmacol; 2024 Jun; 181(12):1857-1873. PubMed ID: 38382564
[TBL] [Abstract][Full Text] [Related]
10. Fungicidal efficacy of various honeys against fluconazole-resistant Candida species isolated from HIV
Shokri H; Sharifzadeh A
J Mycol Med; 2017 Jun; 27(2):159-165. PubMed ID: 28159362
[TBL] [Abstract][Full Text] [Related]
11. Candida species isolated from different body sites and their antifungal susceptibility pattern: Cross-analysis of Candida albicans and Candida glabrata biofilms.
Cataldi V; Di Campli E; Fazii P; Traini T; Cellini L; Di Giulio M
Med Mycol; 2017 Aug; 55(6):624-634. PubMed ID: 27915303
[TBL] [Abstract][Full Text] [Related]
12. 2-amino-nonyl-6-methoxyl-tetralin muriate activity against Candida albicans augments endogenous reactive oxygen species production --a microarray analysis study.
Liang RM; Yong XL; Jiang YP; Tan YH; Dai BD; Wang SH; Hu TT; Chen X; Li N; Dong ZH; Huang XC; Chen J; Cao YB; Jiang YY
FEBS J; 2011 Apr; 278(7):1075-85. PubMed ID: 21251230
[TBL] [Abstract][Full Text] [Related]
13. Potent in vitro synergism of fluconazole and berberine chloride against clinical isolates of Candida albicans resistant to fluconazole.
Quan H; Cao YY; Xu Z; Zhao JX; Gao PH; Qin XF; Jiang YY
Antimicrob Agents Chemother; 2006 Mar; 50(3):1096-9. PubMed ID: 16495278
[TBL] [Abstract][Full Text] [Related]
14. Identification and antifungal susceptibility of Candida species isolated from bloodstream infections in Konya, Turkey.
Dagi HT; Findik D; Senkeles C; Arslan U
Ann Clin Microbiol Antimicrob; 2016 May; 15(1):36. PubMed ID: 27245756
[TBL] [Abstract][Full Text] [Related]
15. Antifungal peptides: a potential new class of antifungals for treating vulvovaginal candidiasis caused by fluconazole-resistant Candida albicans.
Ng SM; Yap YY; Cheong JW; Ng FM; Lau QY; Barkham T; Teo JW; Hill J; Chia CS
J Pept Sci; 2017 Mar; 23(3):215-221. PubMed ID: 28105725
[TBL] [Abstract][Full Text] [Related]
16. Repurposing of Fluvastatin Against Candida albicans CYP450 Lanosterol 14 α-demethylase, a Target Enzyme for Antifungal Therapy: An In silico and In vitro Study.
Rana R; Sharma R; Kumar A
Curr Mol Med; 2019; 19(7):506-524. PubMed ID: 31109273
[TBL] [Abstract][Full Text] [Related]
17. Repurposing of respiratory drug theophylline against Candida albicans: mechanistic insights unveil alterations in membrane properties and metabolic fitness.
Singh S; Fatima Z; Ahmad K; Hameed S
J Appl Microbiol; 2020 Oct; 129(4):860-875. PubMed ID: 32320111
[TBL] [Abstract][Full Text] [Related]
18. Structure-activity relationship studies of ultra-short peptides with potent activities against fluconazole-resistant Candida albicans.
Ng SMS; Yap JM; Lau QY; Ng FM; Ong EHQ; Barkham T; Teo JWP; Alfatah M; Kong KW; Hoon S; Arumugam P; Hill J; Brian Chia CS
Eur J Med Chem; 2018 Apr; 150():479-490. PubMed ID: 29549835
[TBL] [Abstract][Full Text] [Related]
19. The synergy of honokiol and fluconazole against clinical isolates of azole-resistant Candida albicans.
Jin J; Guo N; Zhang J; Ding Y; Tang X; Liang J; Li L; Deng X; Yu L
Lett Appl Microbiol; 2010 Sep; 51(3):351-7. PubMed ID: 20681969
[TBL] [Abstract][Full Text] [Related]
20. Repurposing a human acetyl-CoA carboxylase inhibitor firsocostat to treat fungal candidiasis alone and in combination.
Chen T; Yao J; Quan K; Xu J; Hang X; Tong Q; Liu G; Luo P; Zeng L; Feng G; Bi H
Antimicrob Agents Chemother; 2024 Jan; 68(1):e0113123. PubMed ID: 38018962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
